Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

被引：0

作者：

Masatoshi Kudo

Takuji Okusaka

Kenta Motomura

Izumi Ohno

Manabu Morimoto

Satoru Seo

Yoshiyuki Wada

Shinpei Sato

Tatsuya Yamashita

Masayuki Furukawa

Takeshi Aramaki

Seijin Nadano

Kazuyoshi Ohkawa

Hirofumi Fujii

Toshihiro Kudo

Junji Furuse

Hiroki Takai

Gosuke Homma

Reigetsu Yoshikawa

Andrew X. Zhu

机构：

[1] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[2] National Cancer Center Hospital,Graduate School of Medicine

[3] Aso Iizuka Hospital,Graduate School of Medicine

[4] National Cancer Center Hospital East,Graduate School of Medicine

[5] Kanagawa Cancer Center,undefined

[6] Kyoto University,undefined

[7] National Hospital Organization Kyushu Medical Center,undefined

[8] Kyoundo Hospital,undefined

[9] Sasaki Institute,undefined

[10] Kanazawa University,undefined

[11] National Hospital Organization Kyushu Cancer Center,undefined

[12] Shizuoka Cancer Center Hospital,undefined

[13] National Hospital Organization Shikoku Cancer Center,undefined

[14] Osaka International Cancer Institute,undefined

[15] Jichi Medical University,undefined

[16] Osaka University,undefined

[17] Kyorin University Faculty of Medicine,undefined

[18] Eli Lilly Japan K.K.,undefined

[19] Massachusetts General Hospital Cancer Center,undefined

[20] Harvard Medical School,undefined

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Alpha-fetoprotein; Hepatocellular carcinoma; Japanese subanalysis; Ramucirumab; VEGFR2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 639

页数：12

共 50 条

[41] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu, A. X.
Galle, P. R.
Kudo, M.
Finn, R.
Yang, L.
Abada, P.
Llovet, J. M.
ANNALS OF ONCOLOGY, 2016, 27
[42] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
Zhu, Andrew X.
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Yang, Ling
Abada, Paolo
Chang, Shao-Chun
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[43] Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein
Giannini, Edoardo G.
Trevisani, Franco
HEPATOBILIARY SURGERY AND NUTRITION, 2019, 8 (05) : 515 - 518
[44] Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
Finn, Richard S.
Kudo, Masatoshi
Kang, Yoon-Koo
Yen, Chia-Jui
Galle, Peter R.
Llovet, Josep
Assenat, Eric
Brandi, Giovanni
Lim, Ho Yeong
Pracht, Marc
Rau, Kun Ming
Merle, Philippe
Motomura, Kenta
Ohno, Izumi
Daniele, Bruno
Shin, Dongbok
Gerken, Guido
Abada, Paolo
Hsu, Yanzhi
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[45] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu, Andrew X.
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Yang, Ling
Abada, Paolo
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Zhu, Andrew X.
Kang, Yoon-Koo
Yen, Chia-Jui
Finn, Richard S.
Galle, Peter R.
Llovet, Josep M.
Assenat, Eric
Brandi, Giovanni
Lim, Ho Yeong
Pracht, Marc
Rau, Kun-Ming
Merle, Philippe
Motomura, Kenta
Ohno, Izumi
Daniele, Bruno
Shin, Dongbok
Gerken, Guido
Abada, Paolo
Hsu, Yanzhi
Kudo, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
Ohkawa, Shinichi
Okusaka, Takuji
Kudo, Masatoshi
Hatano, Etsuro
Fujii, Hirofumi
Masumoto, Akihide
Furuse, Junji
Wada, Yoshiyuki
Ishii, Hiroshi
Obi, Shuntaro
Arai, Kuniaki
Kawazoe, Seiji
Yokosuka, Osamu
Ikeda, Masafumi
Ukai, Katsuaki
Morita, Sojiro
Asou, Hiroya
Abada, Paolo B.
Yang, Ling
Zhu, Andrew X.
ANNALS OF ONCOLOGY, 2015, 26 : 94 - 94
[48] Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
Llovet, Josep M.
Yen, Chia-Jui
Finn, Richard S.
Kang, Yoon-Koo
Kudo, Masatoshi
Galle, Peter R.
Assenat, Eric
Pracht, Marc
Lim, Ho Yeong
Rau, Kun-Ming
Borg, Christophe
Hiriart, Jean-Baptiste
Daniele, Bruno
Berg, Thomas
Chung, Hyun Cheol
Godinot, Nathalie
Wang, Chunxiao
Hsu, Yanzhi
Schelman, William R.
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib
Personeni, N.
Bozzarelli, S.
Giordano, L.
Rimassa, L.
Pressiani, T.
Tronconi, M. C.
Sclafani, F.
Carnaghi, C.
Santoro, A.
EJC SUPPLEMENTS, 2009, 7 (02): : 394 - 395
[50] Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
Trojan, Jorg
Mollon, Patrick
Daniele, Bruno
Marteau, Florence
Martin, Lidia
Li, Yuxin
Xu, Qing
Piscaglia, Fabio
Zaucha, Renata
Sarker, Debashis
Lim, Ho Yeong
Venerito, Marino
ADVANCES IN THERAPY, 2021, 38 (05) : 2472 - 2490

← 1 2 3 4 5 →